Related Experiment Video
Updated: May 18, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Refractory neuro-Behçet treated by tocilizumab: a case report
P Urbaniak1, P Hasler, S Kretzschmar
1Rheumaklinik und Institut für Physikalische Medizin und Rehabilitation, Kantonsspital Aarau AG, CH-5001Aarau, Switzerland. piotr.urbaniak@usz.ch
Clinical and Experimental Rheumatology
|October 2, 2012
Summary
Behçet's disease affecting the central nervous system can be challenging to treat. Tocilizumab, an IL-6 receptor inhibitor, effectively improved neurological symptoms and inflammation in a patient refractory to other therapies.
Area of Science:
- Neuroimmunology
- Rheumatology
- Clinical Neurology
Background:
- Behçet's disease is a multisystem inflammatory disorder.
- Central nervous system (CNS) involvement presents significant challenges in treatment.
- Conventional immunosuppressants and anti-TNF agents like infliximab may fail.
Observation:
- A patient experienced progressive leg weakness and reduced walking distance due to CNS Behçet's disease.
- Cerebrospinal fluid analysis revealed significant inflammation with elevated Interleukin-6 (IL-6).
Findings:
- Treatment with tocilizumab, an anti-IL-6 receptor antibody, was initiated.
- Tocilizumab administration led to improved inflammatory markers.
- The patient demonstrated a satisfactory increase in walking distance.
Implications:
- Targeting IL-6 may be a viable therapeutic strategy for refractory CNS Behçet's disease.
- Tocilizumab offers a potential treatment option for patients unresponsive to standard therapies.
- Further research is warranted to explore IL-6 blockade in neuroinflammatory conditions.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:26Nephrotic Syndrome II : Assessment and Medical Management
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:23Gastritis III: Clinical Manifestations and Management
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...